Abstract

Alginate cell-based therapy requires further development focused on clinical application. To assess engraftment, risk of mutations and therapeutic benefit studies should be performed in an appropriate non-human primate model, such as the common marmoset (Callithrix jacchus). In this work we encapsulated amnion derived multipotent stromal cells (MSCs) from Callithrix jacchus in defined size alginate beads using a high voltage technique. Our results indicate that i) alginate-cell mixing procedure and cell concentration do not affect the diameter of alginate beads, ii) encapsulation of high cell numbers (up to 10×106 cells/ml) can be performed in alginate beads utilizing high voltage and iii) high voltage (15–30 kV) does not alter the viability, proliferation and differentiation capacity of MSCs post-encapsulation compared with alginate encapsulated cells produced by the traditional air-flow method. The consistent results were obtained over the period of 7 days of encapsulated MSCs culture and after cryopreservation utilizing a slow cooling procedure (1 K/min). The results of this work show that high voltage encapsulation can further be maximized to develop cell-based therapies with alginate beads in a non-human primate model towards human application.

Highlights

  • Cell-based therapies are under development to treat a wide range of acute and chronic diseases

  • The strength of electric field ranges from 1–10 V/cm of constant voltage for gel electrophoresis up to 100 kV/cm of pulse high voltage for conventional electroporation [32] and supra-electroporation causing high density nanopore formation in all cell membranes [33]

  • The multipotent stromal cells’’ (MSC) derived from a marmoset amnion proved to be true multipotent stromal cells with ‘‘stemness’’ and plasticity

Read more

Summary

Introduction

Cell-based therapies are under development to treat a wide range of acute and chronic diseases. To date, they have been successfully applied in treatments of the central and peripheral nervous system [1], bone and cartilage regeneration, hepatic fibrosis and cardiac insufficiencies [2,3]. The main challenge in such allogenic therapies is the suppression of the host immune system prior to and during the treatment. Cells can be encapsulated into polymer matrices with semi-permeable properties; these shield transplanted cells from immune responses, while allowing controlled release of drugs and cellular products [6]. Most matrices mimic the extra-cellular matrix and provide the cells with a niche-like environment during post-transplantation (Figure 1A)

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call